Product menu

Picture of doctor speaking to patient
Incorporating SHINGRIX into your practice

Incorporating SHINGRIX into your practice involves proper administration, discussing disease risk and vaccination, and ensuring series completion.

PREV
NEXT

Dosing and administration

SHINGRIX is a non-live, recombinant vaccine that is indicated for the prevention of shingles in adults ≥50 years old and in adults 18 years of age or older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.1

calender

Given as a 2-dose series:1

The second dose can be administered 2 to 6 months after the first dose.

For individuals who are or will be immunodeficient, or immunosuppressed and who would benefit from a shorter vaccination schedule, the second dose can be given 1 to 2 months after the initial dose. 

vials

Supplied as two vials for reconstitution:1

SHINGRIX is to be reconstituted only with the accompanying adjuvant suspension. 

tube icon

Refrigerate, do NOT freeze:1

Prior to reconstitution, the vaccine should be stored between 2°C and 8°C. After reconstitution, the vaccine should be used promptly. If not possible, the vaccine is stable for six hours after reconstitution when refrigerated, after which it should be discarded. 

Injection icon

Intramuscular (IM) injection only:1

Preferably in the deltoid muscle.

Refer to the Product Monograph for complete dosing and administration information.

Counselling your patients on shingles vaccination

Warning icon

Explain their risk of shingles:

Risk increases with age, especially after 50 years old2,3

Shingles can be painful and lead to serious complications2

Number icon

Stress the protection benefit of both doses:1

SHINGRIX is a 2-dose series

The second dose is given 2 to 6 months after the first dose

The second dose is important to ensure maximum vaccine efficacy and duration of protection

The need for booster doses following the primary vaccination schedule has not been established

For individuals who are or will be immunodeficient, or immunosuppressed and who would benefit from a shorter vaccination schedule, the second dose can be given 1 to 2 months after the initial dose. 

chat icon

Tell them what to expect:

The specific side effects they are likely to encounter

The median duration of these events

Ensuring series completion

Bigcalender icon

Schedule the follow-up immediately:1

Patients can receive the second dose in as soon as 2 months (and any time between 2 and 6 months)

Phone icon

Call ahead:

Have your office staff call patients in advance of their follow-up

hand icon

Encourage reminder:

Once you set a date, have your patients place a reminder in their calendar

montor Icon

Suggest online resources:

Patients can sign up for email, text, and phone reminders at SHINGRIX.CA*

* The SHINGRIX.ca web page is open to the general public.

Co-administration of SHINGRIX with other vaccines1

SHINGRIX can be given concomitantly with the following vaccines:

  • Unadjuvanted seasonal influenza vaccine
  • 23-valent pneumococcal polysaccharide vaccine (PPV23)
  • Fever and shivering were more frequent when PPV23 vaccine was co-administered with SHINGRIX
  • Reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) 

The vaccines should be administered at different injection sites.

View reconstitution instructions for SHINGRIX

You and your office staff can learn how to administer SHINGRIX step by step.

90% Efficacy

The efficacy profile of SHINGRIX in adults ≥50 years was studied in two phase III trials with 29,305 patients

Vaccine efficacy profile was studied in subjects ≥50 years old (ZOE-50) and subjects ≥70 years old (ZOE-70).1

Learn more
Patient icon

Meet the patients that are eligible to receive SHINGRIX

Nearly everyone ≥50 years old should be protected against shingles.4

Learn more
Virus icon

What was shown to be the dominant driver of shingles?

Learn about age-related decline in immunity.2

Learn more

References:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  2. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30.
  3. Government of Canada. Canadian Immunization Guide: Part 4 – Active Vaccines. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-(shingles)-vaccine.html. Accessed March 5, 2018.
  4. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.

Trademarks are owned by or licensed to the GSK group of companies.

©2022 GSK Group of Companies or its licensor.

10661 | 06/23